Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:39:19 EDT Mon 09 Mar 2026
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:ZVRA - ZEVRA THERAPEUTICS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
ZVRA - Q0.310.59·10.800.89.12+0.141.61,948.518,19811,4818.81  9.12  8.7313.16  6.1919:59:4516:0515 min RT 2¢

Recent Trades - Last 10 of 11481
Time ETExPriceChangeVolume
19:59:45Q10.751.7791
19:59:32Q10.74991.76991
19:59:10Q10.691.711,000
19:58:34Q10.641.66120
19:58:28Q10.6311.651135
19:57:57Q10.64021.6602200
19:57:36Q10.65011.670150
19:57:36Q10.65011.6701250
19:55:25Q10.601.62550
19:55:09Q10.601.6287

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-03-09 16:05U:ZVRANews ReleaseZevra Reports Fourth Quarter and Full Year 2025 Financial Results
2026-03-05 07:30U:ZVRANews ReleaseZevra Therapeutics Appoints Justin Renz as Chief Financial Officer
2026-03-02 07:30U:ZVRANews ReleaseZevra Therapeutics Announces Details for Q4 and Full Year 2025 Financial Results Call
2026-02-25 07:30U:ZVRANews ReleaseZevra Therapeutics to Present at the Citizens Life Sciences Conference
2026-02-04 07:30U:ZVRANews ReleaseZevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA(TM) in Patients with Neimann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium(TM)
2026-02-02 07:30U:ZVRANews ReleaseZevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026
2026-01-26 07:30U:ZVRANews ReleaseZevra Therapeutics to Present Multiple Analyses on MIPLYFFA(TM) at the 22nd Annual WORLDSymposium(TM)
2026-01-08 07:30U:ZVRANews ReleaseZevra Therapeutics to Present at the J.P. Morgan 44th Annual Healthcare Conference
2025-12-29 07:30U:ZVRANews ReleaseZevra Therapeutics Executes Distribution Agreement to Broaden Access to MIPLYFFA(TM) for the Treatment of Niemann-Pick Disease Type C (NPC)
2025-12-12 16:30U:ZVRANews ReleaseZevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2025-12-02 07:30U:ZVRANews ReleaseZevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD
2025-11-20 16:05U:ZVRANews ReleaseZevra Therapeutics, Inc. Announces CFO Transition
2025-11-05 16:05U:ZVRANews ReleaseZevra Reports Third Quarter 2025 Financial Results and Corporate Update
2025-10-29 07:30U:ZVRANews ReleaseZevra Therapeutics to Participate in the Guggenheim Healthcare Innovation Conference
2025-10-27 07:30U:ZVRANews ReleaseZevra Therapeutics Announces Details for Q3 2025 Financial Results Call
2025-10-06 17:51U:ZVRANews ReleaseZevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2025-09-18 07:30U:ZVRANews ReleaseZevra Therapeutics Announces Upcoming Oral Presentation at the International Niemann-Pick Disease Alliance (INPDA) Meeting and Poster Presentations at the Child Neurology Society (CNS) Conference on MIPLYFFA(TM) (arimoclomol) and OLPRUVA(TM) (sodium pheny
2025-09-04 07:30U:ZVRANews ReleaseZevra Therapeutics Presents Positive New Data Supporting Foundational Role of MIPLYFFA(TM) (arimoclomol) for the Treatment of Niemann-Pick Disease Type C at the International Congress of Inborn Errors of Metabolism (ICIEM)
2025-08-28 07:30U:ZVRANews ReleaseZevra Therapeutics Announces Multiple Datasets on MIPLYFFA(TM) (arimoclomol) to be Presented at the International Congress of Inborn Errors of Metabolism (ICIEM)
2025-08-26 07:30U:ZVRANews ReleaseZevra Therapeutics to Participate at Upcoming Investor Conferences in September